Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Zweegman, Sonja  [Clear All Filters]
2013
Schuurhuis GJ, Meel MH, Wouters F, Min LA, Terwijn M, de Jonge NA, Kelder A, Snel AN, Zweegman S, Ossenkoppele GJ, et al. Normal Hematopoietic Stem Cells within the AML Bone Marrow Have a Distinct and Higher ALDH Activity Level than Co-Existing Leukemic Stem Cells. PLoS One. 2013;8(11):e78897.
2014
Terwijn M, Zeijlemaker W, Kelder A, Rutten AP, Snel AN, Scholten WJ, Pabst T, Verhoef G, Löwenberg B, Zweegman S, et al. Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia. PLoS One. 2014;9(9):e107587.
Sonneveld P, Asselbergs E, Zweegman S, van der Holt B, Kersten MJosé, Vellenga E, van Marwijk-Kooy M, Broyl A, de Weerdt O, Lonergan S, et al. Phase 2 study of carfilzomib, thalidomide and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. Blood. 2014.
2015
Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJose', van Oers M, Raymakers R, Minnema MC, Zweegman S, Bos G, Schaap N, et al. Reduced relapse rate in upfront tandem autologous/reduced intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression free and not of overall survival. Haematologica. 2015.
2016
Zweegman S, van der Holt B, Mellqvist U-H, Salomo M, Bos GMJ, Levin M-D, Visser-Wisselaar H, Hansson M, van der Velden AWG, Deenik W, et al. Lenalidomide plus melphalan and prednisone, followed by lenalidomide maintenance versus thalidomide plus melphalan and prednisone, followed by thalidomide maintenance; results of the randomised phase 3 HOVON 87/NMSG18 trial. Blood. 2016.
2018
Verhagen HJMP, van Gils N, Martiañez T, van Rhenen A, Rutten A, Denkers F, de Leeuw DC, Smit MA, Tsui M-L, Klootwijk LLE de Vos, et al. IGFBP7 Induces Differentiation and Loss of Survival of Human Acute Myeloid Leukemia Stem Cells without Affecting Normal Hematopoiesis. Cell Rep. 2018;25(11):3021-3035.e5.
2019
Bringhen S, Milan A, D'Agostino M, Ferri C, Wäsch R, Gay F, Larocca A, Offidani M, Zweegman S, Terpos E, et al. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A Consensus Paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. J Intern Med. 2019.
Moshaver B, Wouters RF, Kelder A, Ossenkoppele GJ, Westra GAH, Kwidama Z, Rutten AR, Kaspers GJL, Zweegman S, Cloos J, et al. Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia. Leuk Res. 2019;81:27-34.
2020
Roussel M, Moreau P, Hébraud B, Laribi K, Jaccard A, Dib M, Slama B, Dorvaux V, Royer B, Frenzel L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial. Lancet Haematol. 2020;7(12):e874-e883.
2021
Aydin M, Tang MWai, Wondergem MJ, de Leeuw DC, Wegman JJ, Biemond BJ, van de Donk NWCJ, Zweegman S, Meijer E, Nur E. High-dose melphalan in 1 day versus over 2 days followed by autologous stem cell transplantation as consolidation treatment in patients with multiple myeloma. Br J Haematol. 2021.
Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22(3):e105-e118.
2023
Ludwig H, Terpos E, van de Donk N, Mateos M-V, Moreau P, Dimopoulos M-A, Delforge M, Rodriguez-Otero P, San-Miguel J, Yong K, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023;24(6):e255-e269.
van de Donk NWCJ, Minnema MC, van der Holt B, Schjesvold F, Wu KLung, Broijl A, Roeloffzen WWH, Gadisseur A, Pietrantuono G, Pour L, et al. Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study. Lancet Oncol. 2023.